Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Verastem Inc (VSTM)

Verastem Inc (VSTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,161
  • Shares Outstanding, K 74,350
  • Annual Sales, $ 26,720 K
  • Annual Income, $ -72,430 K
  • 60-Month Beta 2.85
  • Price/Sales 10.72
  • Price/Cash Flow N/A
  • Price/Book 6.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +10.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.73 +19.08%
on 01/22/20
2.23 -7.62%
on 02/05/20
+0.16 (+8.42%)
since 01/17/20
3-Month
0.85 +142.35%
on 11/19/19
2.23 -7.62%
on 02/05/20
+1.20 (+139.42%)
since 11/18/19
52-Week
0.83 +148.19%
on 11/18/19
3.66 -43.72%
on 03/21/19
-1.24 (-37.58%)
since 02/15/19

Most Recent Stories

More News
Verastem Oncology Announces Dosing of First Patient in CSPC's Chinese Study Evaluating COPIKTRA(R) (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma

Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of...

VSTM : 2.06 (+3.00%)
Biotechnological Breakthroughs Help Revamp the Fight Against Cancer

Biotechnology plays an important role throughout various sectors by improving industry standards, services, and developing new products. While agriculture, material science and environmental science are...

TOMDF : 0.0350 (-12.50%)
AGEN : 4.00 (+2.56%)
LPTX : 2.30 (+6.98%)
TRIL : 3.70 (+0.54%)
VSTM : 2.06 (+3.00%)
Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up

Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.

MRK : 82.60 (+0.17%)
LLY : 141.01 (-0.08%)
VSTM : 2.06 (+3.00%)
INFI : 1.36 (unch)
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766

--Clinical Data Presentation and Regulatory Discussions Planned for 1H 2020

VSTM : 2.06 (+3.00%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients,...

VSTM : 2.06 (+3.00%)
Implied Volatility Surging for Verastem (VSTM) Stock Options

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

VSTM : 2.06 (+3.00%)
Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

--Data Presented Support Potential of Duvelisib Across Indications, Lines of Therapy and in Combination

VSTM : 2.06 (+3.00%)
Implied Volatility Surging for Verastem (VSTM) Stock Options

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

VSTM : 2.06 (+3.00%)
Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA(R) (duvelisib)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer...

VSTM : 2.06 (+3.00%)
Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award

Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of...

VSTM : 2.06 (+3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade VSTM with:

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

2nd Resistance Point 2.13
1st Resistance Point 2.10
Last Price 2.06
1st Support Level 1.99
2nd Support Level 1.91

See More

52-Week High 3.66
Fibonacci 61.8% 2.58
Fibonacci 50% 2.25
Last Price 2.06
Fibonacci 38.2% 1.91
52-Week Low 0.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar